Discussion & conclusion

7.1

Discussion

The analytical technique developed for this assignment was primarily shaped by the nature of the sample and the specific chemical degradation risk associated with acetylcysteine. Because the sample is a homogenous, single-phase aqueous system, sample preparation did not require the API extraction step typically used with semi-solid dosage forms. Instead, the analytical method must focus on distinguishing the chemical degradation products of acetylcysteine — principally N,N′-diacetylcystine, cysteine, and cystine — formed via the oxidation of the free reactive thiol (-SH) group. Therefore, High-Performance Liquid Chromatography (HPLC) was chosen as the primary method, since chromatographic separation allows the intact drug to be measured independently of any degradation products present in the sample.

Since there is no official British Pharmacopoeia monograph for an acetylcysteine nebulising solution, the official Acetylcysteine Injection monograph was adapted for this assignment. This approach was considered appropriate given that both preparations are sterile, unpreserved aqueous acetylcysteine solutions sharing the same excipients (disodium edetate as a chelating agent, with pH adjustment to limit oxidation). The chromatographic conditions and working concentrations used in the injection monograph were also applied to this assay.

Notably, the official assay method used for acetylcysteine content in aqueous preparations is iodometric titration, with HPLC reserved for the Related Substances (Impurity) test. The rationale for choosing HPLC as the primary method lies with a specific limitation of iodometric titration: because iodine oxidises any free thiol present, titration measures the total reducible sulfhydryl content and consequently cannot measure the acetylcysteine content specifically. HPLC was therefore chosen as the primary method due to its superior specificity, while iodometric titration was incorporated as an independent cross-validation check.

The validation strategy for this assay was designed to address four core parameters — linearity, accuracy, precision and specificity — in line with recognised pharmaceutical validation principles (Pharmaffiliates, 2026; ICH, n.d.). Linearity was addressed through a five-point calibration range with statistical evaluation via regression analysis, while accuracy and precision were designed to be assessed against the British Pharmacopoeia's acceptance criteria for Acetylcysteine Injection (95.0–105.0 % recovery and %RSD ≤ 2 %, respectively). Specificity was addressed inherently through the chromatographic separation itself, since HPLC allows the acetylcysteine peak to be evaluated independently of any co-eluting impurities.

To further strengthen the accuracy assessment, cross-validation against iodometric titration was incorporated. However, because this titration reacts with any free thiol group present rather than acetylcysteine specifically, it was deliberately used only as a supporting precautionary check rather than as a specificity-confirming method in its own right, since its non-selective nature means it cannot itself rule out interference from thiol-containing degradation products.

Certain limitations must be acknowledged. Acetylcysteine's oxidative instability means that even minor delays or inconsistencies in sample handling between preparation and injection could introduce variability; the precautionary measures built into the sampling and preparation sections were intended to mitigate this, but cannot completely eliminate it. Additionally, because this method was adapted from a parenteral monograph rather than one specific to nebulising solutions, its performance has not been independently validated against an official reference.

7.2

Conclusion

The HPLC method developed for this assignment is designed to provide a specific, accurate and precise means of quantifying acetylcysteine content in a 20 % w/v nebulising solution, while remaining capable of distinguishing between the intact drug and its principal oxidative degradation products. Its performance was intended to be confirmed through a structured validation approach assessing linearity, accuracy and precision against British Pharmacopoeia acceptance criteria, supported by cross-validation against iodometric titration as an additional, though non-selective, precautionary check.